Sytheon Revolutionizes Atopic Dermatitis Treatment with Groundbreaking ActSES®: A Holistic Approach to Skincare

In response to the pressing demand for a sustainable, safe, and cost-effective solution for mild to moderate Atopic Dermatitis (AD), Sytheon introduces its pioneering turnkey product, ActSES®. This revolutionary formula, meticulously crafted and clinically validated by dermatologists from UC-Davis, CA, fills a crucial gap in the market. A concurrent study focusing on pediatric application is already in progress, underscoring Sytheon's commitment to comprehensive dermatological solutions.

Sytheon Unveils Its New Turnkey Product for Treating Atopic Dermatitis

ActSES® stands out as a unique amalgamation of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) and Isosorbide di-caprylate (Hydra Synol® DOI). Sytheon's scientific prowess, reinforced by robust patent protection (U.S. Patents 11,753,414 and 11,753,415), titled "Composition and Methods for Treating Atopic Dermatitis," ensures the product's exclusivity in the skincare arena. Complementing their prior patents (U.S. Patents 10,597,402 & 11,312,725), which elucidate "compositions and methods for restoring epidermal integrity and function and treating dermatological diseases," Sytheon establishes itself as a trailblazer in dermatological innovation.

ActSES® goes beyond mere barrier repair; its unique synergy actively inhibits inflammatory cascades responsible for exacerbating pruritus and cutaneous eruptions associated with chronic AD. The complexity of AD, characterized by the intricate interplay of skin barrier dysfunction and immune dysregulation, is effectively addressed by ActSES®, presenting a multifaceted solution to a persistent challenge.

Sytheon is now on the lookout for an exclusive partnership with a suitable organization to usher in ActSES® into the over-the-counter (OTC) dermatological market. This strategic collaboration aims to make this turnkey product readily available, ensuring a wider reach and greater accessibility for those seeking effective and innovative solutions for managing AD. Sytheon's ActSES® represents a paradigm shift in the treatment of Atopic Dermatitis, embodying sustainability, safety, and cost-effectiveness in a groundbreaking skincare formula.